Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Bill J. Smith, M. Naveed Shaik et al.|Molecular Pharmaceutics|2023Cited by 52
539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in HumansJim Zheng, Winston C. Tse, Stephen R. Yant et al.|Open Forum Infectious Diseases|2018Cited by 15
Lenacapavir Exhibits Atropisomerism—Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Raju Subramanian, Bing Lu et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Discovery ofLenacapavir: First-in-Class Twice-YearlyCapsid Inhibitor for HIV-1 Treatment and Pre-exposure ProphylaxisEda Canales, John O. Link, Winston C. Tse et al.|Journal of Medicinal Chemistry|2025Cited by 11
Intestinal Excretion is a Major Disposition Pathway of Lenacapavir in Rat and DogJim Zheng, Raju Subramanian, Winston C. Tse et al.|The FASEB Journal|2021Cited by 1